Liminatus Pharma (NASDAQ:LIMN) Shares Down 0.3% – What’s Next?

Liminatus Pharma Inc. (NASDAQ:LIMN)’s share price traded down 0.3% on Thursday. The stock traded as low as $3.10 and last traded at $3.11. 12,757 shares traded hands during trading, a decline of 53% from the average session volume of 27,190 shares. The stock had previously closed at $3.12.

Wall Street Analysts Forecast Growth

LIMN has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Liminatus Pharma to a “strong sell” rating in a report on Saturday, August 22nd. Weiss Ratings cut Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company currently has an average rating of “Sell”.

Liminatus Pharma Stock Performance

The business has a fifty day moving average of $3.93 and a two-hundred day moving average of $6.32. The firm has a market capitalization of $3.95 million, a price-to-earnings ratio of -0.13 and a beta of 4.97.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.